Skip to main content

Table 3 Proportion of high risk patients on treatment as recommended by the European guidelines. Proportion of low risk patients and of unclassified patients on treatment.

From: Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: Lessons learned from a health care services study

SCORE risk category
Treatment
(1) CVD (n=103) (2) DM2 (n=260) (3) SCORE ≥5% (n=74) (4) SCORE <5% (n=101) (5) Unclassified(n=563)
  N (%) Δ(%) N (%) Δ(%) N (%) Δ(%) N (%) N (%)
ANTIHYPERTENSIVES   3.6   13.1   6.7   
• Current 34 (41.0)   86 (40.4)   38 (51.4)   71 (70.3) 382 (67.9)
• Recommended 37 (44.6)   114 (53.5)   43 (58.1))   - -
LLD   30.2   38.9   47.9   
• Current 18 (41.9)   50 (36.8)   27 (38.0)   46 (45.5) 173 (30.7)
• Recommended 31 (72.1)   103 (75.7)   61 (85.9)   - -
ASPIRIN   53.4   87.7   89.2   
• Current 48 (46.6)   32 (12.3)   8 (10.8)   25 (24.8) 13(2.3)
• Recommended 103 (100)   260 (100)   74 (100)   - -
  1. SCORE risk categories:
  2. (1): Patients with CVD +/- DM2
  3. (2): Patients with DM2 (no CVD)
  4. (3): Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of ≥5% for developing a fatal CVD event; Patients with TC ≥320 mg/dl (≥8 mmol/l) or LDL ≥240 mg/7 dl (≥6 mmlo/l) or BP ≥180/110 mmHg.
  5. (4): Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of <5% for developing a fatal CVD event.
  6. (5): Patients with neither CVD nor DM2 but with missing data on risk factors for score calculation
  7. Values are for those patients with available data